← boardnext 2026-12
JAGX
Napo Pharmaceuticals, Inc.distress 9/10 · high distress / dilution risk$1.22-8%today-99% from 52w high
Lead: rare intestinal failure
Revenue
$20M
Liquidity
$7M
Runway
1.0 yrs
Shares 1y
+2010%
Price & events
-95.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-8.4%
1D
-8.7%
1W
-52.4%
1M
-91.2%
3M
-95.4%
6M
-98.5%
1Y
-99.9%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $208.82M
- Volume
- 14.46K
- 52 Week Range
- $1.22 – $94.50
- Total Shares
- 171.35M
- Float Shares
- 576.58K
- Short %
- 1.52%
- % Held by Insiders
- 0.64%
- % Held by Institutions
- 0.15%
- RVOL
- 0.17x
- Beta
- -0.09
Pipeline stages · 1 programs
Crofelemer Powder for Oral Solution
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 2/3 | Crofelemer Powder for Oral Solution | Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases | — | active not recruiting |
Catalyst news & presentations · 9
- mid-2027Guided 55%regulatory submissionFiled (NDA/BLA)crofelemer · Targeting NDA submission for powder-for-oral-solution formulation.SEC 8-K
- 2026-08-13Confirmed 100%earningsEarningsEarnings releaseyahoo
- June 2026conferencedata presentationsecondarycrofelemer · late-breaking abstract presentation at ESPGHAN Annual MeetingSEC 8-K
- June 10, 2026conferencedata presentationsecondaryLisa Conte presenting virtually at the Emerging Growth ConferenceSEC 8-K
- 2026-01-12partnershipMytesi; Canalevia-CA1 · Exclusive U.S. license to Future Pak with $18M upfront and up to $20M milestones.SEC 8-K
- December 8, 2025 from 3:25pm - 3:35pm Easternconferencedata presentationsecondaryCEO presenting at Emerging Growth Conference to update on near-term catalystsSEC 8-K
- 2025-10-02fda agreementcrofelemer · Completed FDA meeting for advice on advancing placebo-controlled trial in MVID for possible expedited approval pathwaySEC 8-K
- August 20conferencedata presentationsecondaryCEO presenting at Emerging Growth Conference to provide updates on near-term catalysts.SEC 8-K
- April 30, 2025 at 8:30 AM Easternconferencedata presentationsecondarycrofelemer · Investor webcast reviewing initial results from proof-of-concept IIT of crofelemer for MVID and SBS-IF.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-05-19First BerlinBuy
Competitors — rare intestinal failure
- none identified
Recent news
- 2026-07-22Jaguar Health (JAGX) Secures Compassionate Use for Crofelemer in EU - GuruFocus
- 2026-07-22Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) - Yahoo Finance
- 2026-07-22Jaguar Reports Up to 48% Lower Weekly Support in One MVID Patient - Stock Titan
- 2026-07-19Jaguar Health (JAGX) Registration filing Summary - Quartr
- 2026-07-19Jaguar Health (JAGX) Registration filing Summary - Quartr
- 2026-07-18Jaguar Health Company Profile & Introduction - Moomoo
- 2026-07-18JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
- 2026-07-16Enterprise value to EBIT forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.